Vol. 1 No. 9 (2005)

Published: 3 June 2009

3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005

Abstracts

The scale of the problem

M H Prins

https://doi.org/10.4081/hmr.v1i9.309

156

PDF: 179
- PDF
Occult cancer and idiopathic venous thromboembolism

A Piccioli

https://doi.org/10.4081/hmr.v1i9.310

188

PDF: 640
- PDF
Tissue factor-bearing microparticles and cancer-associated thrombosis

B Furie

https://doi.org/10.4081/hmr.v1i9.311

216

Untitled: 0
Blood-borne tissue factor

NS Key

https://doi.org/10.4081/hmr.v1i9.312

253

PDF: 283
- PDF
Tissue factor pathway inhibitor and cancer

Y Gruel, J Rollin, S Regina, S Iochmann, F Hube, P Reverdiau

https://doi.org/10.4081/hmr.v1i9.313

171

PDF: 626
- PDF
Tissue factor-PAR2 signaling crosstalk in cancer and angiogenesis

W Ruf

https://doi.org/10.4081/hmr.v1i9.314

181

PDF: 453
- PDF
Oncogenic events regulating tissue factor expression

Y Yu, L May, V Lhotak, C Milsom, Y Li, S Shahrzad, S Shirasawa, JI Weitz, BL Coomber, J Micelef, A Guha, P Klement, N Klement, JW Rak

https://doi.org/10.4081/hmr.v1i9.315

186

PDF: 329
- PDF
Hemostatic factors support metastasis by impeding NK cell-mediated elimination of embolic tumor cells

JL Degen, JV Massari, KE Talmage, CM La Jeunesse, KW La Jeunesse, MJ Flick

https://doi.org/10.4081/hmr.v1i9.316

236

PDF: 367
- PDF
The met oncogene drives a genetic program linking cancer to hemostasis

C Boccaccio, PM Comoglio

https://doi.org/10.4081/hmr.v1i9.317

174

PDF: 252
- PDF
Cytokine GRO-a is pivotal in thrombin-induced angiogenesis

S Karpatkin

https://doi.org/10.4081/hmr.v1i9.318

193

PDF: 355
- PDF
Low molecular weight heparin and survival in cancer

AK Kakkar

https://doi.org/10.4081/hmr.v1i9.319

178

PDF: 189
- PDF
Fibrinolytics, enzyme inhibitors, and cancer survival

M Schmitt, V Magdolen, K Mengele, U Reuning, J Foekens, EP Diamandis, N Harbeck

https://doi.org/10.4081/hmr.v1i9.320

185

PDF: 680
- PDF
Vitamin k, warfarin and prothrombin: an alternate pathway to improve cancer survival

HA Liebman

https://doi.org/10.4081/hmr.v1i9.321

196

PDF: 261
- PDF
Future perspective of clinical trials of antithrombotics and cancer survival

R Er

https://doi.org/10.4081/hmr.v1i9.322

172

PDF: 202
- PDF
Clinical trials with angiogenesis inhibitors

G Giaccone, H van Cruijsen

https://doi.org/10.4081/hmr.v1i9.323

194

PDF: 204
- PDF
Vascular complications of endothelium targeting therapies

F Rodeghiero, F Elice

https://doi.org/10.4081/hmr.v1i9.324

178

PDF: 187
- PDF
Commentary on thrombotic and bleeding complications of clinical trials of growth factor inhibitors

CM Kessler

https://doi.org/10.4081/hmr.v1i9.325

161

PDF: 718
- PDF
Lymphangiogenesis: a new paradigm for cancer progression and therapy

K Alitalo

https://doi.org/10.4081/hmr.v1i9.326

146

PDF: 175
- PDF
Hemorrhage and thrombosis in acute leukemia

T Barbui

https://doi.org/10.4081/hmr.v1i9.327

400

PDF: 3665
- PDF
Prevention of disseminated intravascular coagulation in cancer

M Levi

https://doi.org/10.4081/hmr.v1i9.328

410

PDF: 1322
- PDF
Bleeding and thrombosis in childhood cancer

U Nowak-Gött

https://doi.org/10.4081/hmr.v1i9.329

183

PDF: 670
- PDF
The protein C system in inflammation and cancer: a critical role for thrombomodulin

H Spronk, H Ten Cate

https://doi.org/10.4081/hmr.v1i9.330

179

PDF: 210
- PDF
Heparin effects in metastasis and Trousseau's syndrome: anticoagulation is not the primary mechanism

JL Stevenson, SH Choi, M Wahrenbrock, A Varki, NM Varki

https://doi.org/10.4081/hmr.v1i9.331

327

PDF: 223
- PDF
The impact of heparanase on cancer progression

I Vlodavsky, N Ilan, G Abboud-Jarrous, Y Nadir, B Brenner, A Naggi, C Pisano, B Casu

https://doi.org/10.4081/hmr.v1i9.332

200

PDF: 736
- PDF
Inhibition of tumor growth by heparins in vivo

SA Mousa

https://doi.org/10.4081/hmr.v1i9.333

167

PDF: 207
- PDF
Clinical outcomes in cancer patients with concurrent venous thromboembolism: findings from the RIETE registry

M Monreal, C Falgá, B Vilaseca, C Suárez, F Gabriel, C Carles Tolosa, J Montes

https://doi.org/10.4081/hmr.v1i9.334

219

PDF: 532
- PDF
Unresolved problems in venous thromboembolism treatment in cancer

A Agnelli, M Verso

https://doi.org/10.4081/hmr.v1i9.335

176

PDF: 416
- PDF
The role of new antithrombotics

HR Büller

https://doi.org/10.4081/hmr.v1i9.337

147

PDF: 123
- PDF
Modified Heparins as possible inhibitors of metastasis

L Borsig

https://doi.org/10.4081/hmr.v1i9.338

144

PDF: 390
- PDF

Proceedings

Hypercoaugulability

Anna Falanga, Benjamin Brenner, Frederick R Rickles

https://doi.org/10.4081/hmr.v1i9.339

343

PDF: 666
- PDF

Current Issue

Vol. 1 No. 9 (2005)

Abstracts

The scale of the problem

Occult cancer and idiopathic venous thromboembolism

Tissue factor-bearing microparticles and cancer-associated thrombosis

Blood-borne tissue factor

Tissue factor pathway inhibitor and cancer

Tissue factor-PAR2 signaling crosstalk in cancer and angiogenesis

Oncogenic events regulating tissue factor expression

Hemostatic factors support metastasis by impeding NK cell-mediated elimination of embolic tumor cells

The met oncogene drives a genetic program linking cancer to hemostasis

Cytokine GRO-a is pivotal in thrombin-induced angiogenesis

Low molecular weight heparin and survival in cancer

Fibrinolytics, enzyme inhibitors, and cancer survival

Vitamin k, warfarin and prothrombin: an alternate pathway to improve cancer survival

Future perspective of clinical trials of antithrombotics and cancer survival

Clinical trials with angiogenesis inhibitors

Vascular complications of endothelium targeting therapies

Commentary on thrombotic and bleeding complications of clinical trials of growth factor inhibitors

Lymphangiogenesis: a new paradigm for cancer progression and therapy

Hemorrhage and thrombosis in acute leukemia

Prevention of disseminated intravascular coagulation in cancer

Bleeding and thrombosis in childhood cancer

The protein C system in inflammation and cancer: a critical role for thrombomodulin

Heparin effects in metastasis and Trousseau's syndrome: anticoagulation is not the primary mechanism

The impact of heparanase on cancer progression

Inhibition of tumor growth by heparins in vivo

Clinical outcomes in cancer patients with concurrent venous thromboembolism: findings from the RIETE registry

Unresolved problems in venous thromboembolism treatment in cancer

The role of new antithrombotics

Modified Heparins as possible inhibitors of metastasis

Proceedings

Hypercoaugulability

Categories